Reported Friday, Johnson & Johnson's CARVYKTI Approved By The U.S. FDA For Patients With Relapsed Or Refractory Multiple Myeloma Who Have Received At Least One Prior Line Of Therapy
Portfolio Pulse from Benzinga Newsdesk
The U.S. FDA has approved Johnson & Johnson's CARVYKTI® for patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy. This approval, based on the Phase 3 CARTITUDE-4 study, shows a 59% reduction in disease progression or death risk compared to standard therapies, marking a significant advancement in treatment options.
April 08, 2024 | 7:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson's CARVYKTI® receives FDA approval for expanded use in multiple myeloma treatment, based on positive Phase 3 study results.
The FDA approval of CARVYKTI® for an expanded patient base represents a significant milestone for Johnson & Johnson, potentially leading to increased sales and positive market perception. The strong results from the Phase 3 study further bolster the drug's profile, likely contributing to a positive short-term impact on JNJ's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100